leadf
logo-loader
viewAIM ImmunoTech Inc

AIM says first patient dosed with Ampligen in study evaluating it as drug combo to treat patients with cancer and COVID-19

Roswell Park's Phase 1/2a study is gauging the two-drug combo of Ampligen and interferon alpha-2b as a potential treatment for patients with cancer and mild-to-moderate COVID-19

AIM ImmunoTech Inc - AIM says first patient dosed with Ampligen in study evaluating it as drug combo to treat patients with cancer and COVID-19
It is also working on an effective therapy for COVID-19 long haulers - those who diagnosed with the disease and still suffer debilitating symptoms months later

AIM ImmunoTech Inc (NYSEAMERICAN:AIM) (FRA:HXB2) said on Wednesday that it had achieved a milestone in its coronavirus (COVID-19) treatment and prevention efforts with the first patient dosed in a study evaluating its lead drug Ampligen as part of a combination treatment for patients with cancer and COVID-19. 

The Ocala, Florida-based company said that Roswell Park Comprehensive Cancer Center’s Phase 1/2a study evaluating the two-drug combo of AIM’s Ampligen and interferon alpha-2b as a potential early-onset treatment for patients with cancer and mild-to-moderate COVID-19 is “fully underway, with the first patient enrolled and treated on the study.” 

AIM is a collaborator on that clinical trial, which is funded in part through grants from the National Cancer Institute and AIM, as well as institutional support from Roswell Park. AIM said it is providing Ampligen at no charge for the study. More details about this trial, led by Roswell Park co-Principal Investigators, Dr Brahm Segal and Dr Pawel Kalinski, are available at ClinicalTrials.gov. 

READ: AIM ImmunoTech trumpets $54.5M in cash on hand, advances its drug Ampligen as cancer, coronavirus treatment

In addition, AIM is working to develop an intranasal prophylaxis strategy for frontline workers, the elderly and other high-risk patients, including those with co-morbidities such as cancer.

The company has also devoted itself to working on an effective therapy for COVID-19 long haulers, a portion of people who are diagnosed with the disease still suffer persistent and debilitating symptoms months later.

In a statement, AIM CEO Thomas K Equels said: “While major global pharmaceutical companies have largely focused their efforts on the critical need for a COVID-19 vaccine – with Moderna and Pfizer recently announcing significant and hopeful results – AIM believes there is an equally critical health need to develop an early-onset treatment for people already infected with the disease.”

“We greatly appreciate the leadership of Dr Brahm Segal and Dr Pawel Kalinski, as well as the tremendous efforts of the entire team at Roswell Park. We look forward to providing further updates as this critical trial progresses.”

AIM ImmunoTech is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19.

Contact the author Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive

Quick facts: AIM ImmunoTech Inc

Price: 2.07 USD

NYSE:AIM
Market: NYSE
Market Cap: $84.22 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of AIM ImmunoTech Inc named herein, including the promotion by the Company of AIM ImmunoTech Inc in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

IronRidge Resources present latest results from lithium and flagship gold...

IronRidge Resources Limited's (LON:IRR) Vincent Mascolo presents the results of a scoping study for the Ewoyaa lithium project in Ghana to Proactive London. He says it's all about 'location, location, location', Mascolo talks through the qualities of such a resource and the potential...

7 hours, 2 minutes ago

2 min read